Travere Therapeutics Says USPTO Allowed Patent For FILSPARI In FSGS, Expected To Provide Coverage Into October 2037
Share
Why It Matters
Travere Therapeutics got a patent that protects FILSPARI until October 2037. This means the company can sell this medicine without direct competition for many years.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.